Phase 2

Active (not recruiting)

NCT05405361

Empasiprubart (ARGX-117)

View on ClinicalTrials.gov ↗

Timeline

Study Dates

Start Date

—

Est. Completion

—

Enrollment Target

—

Status

Active (not recruiting)

Study Design

Primary Endpoint

Long-term safety, tolerability, efficacy of ARGX-117 (extension of ARDA)

Registry

ClinicalTrials.gov Record

Registry ID

NCT05405361

Direct Link

clinicaltrials.gov/NCT05405361 ↗

Related Treatment

Treatment Being Studied

Empasiprubart (ARGX-117) →